Article

Anecortave acetate program terminated, says Alcon

Alcon announced the termination of the development program designed to evaluate the benefit of anecorative acetate treatment on the risk for developing choroidal neovascularization secondary to age-related macular degeneration.

Heunenberg, Switzerland-Alcon announced the termination of the development program designed to evaluate the benefit of anecorative acetate treatment on the risk for developing choroidal neovascularization secondary to age-related macular degeneration.

The decision followed an interim analysis of studies CO-02-60 A and B, performed after 2,546 patients completed the 24-month time point. It was found that anecorative acetate showed no effect on the primary or secondary endpoints.

The company also terminated two smaller studies with identical designs, being conducted in Asia, CO-04-30 and C-05-34.

Anecorative acetate is still being studied by the company as an anterior juxtascleral depot to reduce IOP in patients with open-angle glaucoma.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.